Atlas Trials

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Clinical trial NCT05095207 · RECRUITING

Trial details

NCT number
NCT05095207
Sponsor
Icahn School of Medicine at Mount Sinai
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Breast CancerMetastasis
Start date
2021-09-20
Primary completion
2027-06-01
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.